Sensus Healthcare, Inc. (SRTS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sensus Healthcare, Inc. (SRTS) Healthcare & Pipeline Overview

Sensus Healthcare, Inc. is a leading manufacturer of superficial radiation therapy devices, providing innovative alternatives to surgery for non-melanoma skin cancers and keloids, leveraging advanced technology to enhance patient care in the medical device sector.

What Is the Investment Thesis for SRTS?

Sensus Healthcare, Inc. operates in the niche market of superficial radiation therapy, which is increasingly recognized as a viable alternative to surgery for treating non-melanoma skin cancers. The company has a market capitalization of approximately $0.07 billion and a gross margin of 37.7%, indicating a solid operational efficiency compared to industry peers. Key growth catalysts include the increasing prevalence of skin cancer, which is projected to rise significantly, driving demand for non-invasive treatment options. Furthermore, Sensus Healthcare's commitment to innovation, as evidenced by its advanced SRT-100 Vision system, positions it favorably within the medical device sector. However, the company faces challenges, including a negative profit margin of -34.5%, which may impact its financial stability if not addressed. Overall, Sensus Healthcare's focus on a specialized market segment and its innovative product offerings present potential growth opportunities, contingent on effective management of operational costs and market expansion strategies.

Based on FMP financials and quantitative analysis

SRTS Key Highlights

Market capitalization of $53.2M reflects a growing presence in the medical device sector.

• Gross margin of 37.7% indicates strong operational efficiency in product offerings.
• Negative profit margin of -34.5% highlights the need for improved cost management.
• Beta of 1.28 suggests higher volatility compared to the broader market.
• No dividend yield, indicating a focus on reinvestment for growth.

Who Are SRTS's Competitors?

SRTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SRTS's Key Strengths?

Innovative technology in superficial radiation therapy.

• Strong gross margin of 37.7%, indicating effective cost management.
• Established market presence in a niche segment of healthcare.
• Experienced leadership team with industry expertise.

What Are SRTS's Weaknesses?

Negative profit margin of -34.5% raises concerns about financial sustainability.

• Limited product range compared to larger competitors.
• Dependence on a specific market segment may expose the company to risks.
• Relatively small employee base may limit operational capacity.

What Could Drive SRTS Stock Higher?

Expansion into international markets to capture growing demand for non-invasive skin cancer treatments.

• Development of new product lines to enhance treatment options and patient outcomes.
• Strategic partnerships with healthcare providers to increase adoption of SRT technology.
• Regulatory approvals for expanded indications to treat a broader range of skin conditions.
• Marketing initiatives to raise awareness of non-invasive treatment options.

What Are the Key Risks for SRTS?

Negative return on equity (-15.8%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition from larger medical device companies may impact market share.
• Regulatory challenges in obtaining approvals for new products could delay growth.
• Market volatility affecting healthcare spending may impact revenue.
• Changes in reimbursement policies could affect the financial viability of treatment options.

What Are the Growth Opportunities for SRTS?

• Expansion into new geographic markets: Sensus Healthcare plans to expand its operations into international markets where the demand for non-invasive skin cancer treatments is rising. The global market for skin cancer therapies is projected to reach $12 billion by 2027, providing significant growth potential for Sensus's innovative products.
• Development of new product lines: The company is focusing on enhancing its product portfolio by developing new devices that integrate advanced imaging technologies. This could lead to improved treatment outcomes and patient satisfaction, further solidifying its market position.
• Partnerships with healthcare providers: Sensus Healthcare is actively seeking partnerships with hospitals and clinics to increase the adoption of its SRT technology. Collaborations can enhance its distribution capabilities and drive sales growth, particularly in underserved markets.
• Increased awareness of non-invasive treatments: As awareness of non-invasive treatment options grows, Sensus Healthcare stands to benefit from a shift in patient preferences. Educational campaigns and clinical studies demonstrating the efficacy of superficial radiation therapy can drive demand for its products.
• Regulatory approvals for expanded indications: The company is pursuing additional regulatory approvals for its devices to treat a broader range of skin conditions. Successful approvals can open new revenue streams and enhance the company's market presence.

What Are SRTS's Competitive Advantages?

• Specialized focus on superficial radiation therapy differentiates Sensus from competitors.
• Innovative product offerings, such as the SRT-100 Vision, enhance treatment precision.
• Established relationships with healthcare providers foster customer loyalty.
• Ongoing commitment to research and development supports continuous product improvement.
• Strong brand recognition in the niche market of non-invasive cancer treatments.

What Does SRTS Do?

Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida. The company focuses on developing and manufacturing radiation therapy devices, specifically utilizing superficial radiation therapy (SRT), a low-energy X-ray technology. Sensus Healthcare's flagship product, the SRT-100, is designed to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as other skin conditions like keloids. The SRT-100 offers patients a non-invasive alternative to traditional surgical treatments. In addition to the SRT-100, the company also provides the SRT-100 Vision, which features a tailored treatment planning application that integrates advanced imaging and dosimetry capabilities for enhanced treatment precision. Sensus Healthcare further expands its offerings with the SRT-100 Plus and the Sentinel service program, which ensures system protection for customers. Additionally, the company provides in-office laser rental services and sells disposable radiation safety items, including lead shielding replacements and protective gear. With a workforce of 54 employees, Sensus Healthcare is committed to improving patient outcomes through innovative medical solutions and has established a significant presence in the healthcare market by focusing on non-invasive treatment options.

What Products and Services Does SRTS Offer?

• Manufacture and sell radiation therapy devices for treating skin cancers.
• Offer the SRT-100, a non-invasive treatment alternative for non-melanoma skin cancers.
• Provide the SRT-100 Vision, which includes advanced treatment planning and imaging capabilities.
• Sell disposable radiation safety items and lead shielding replacements.
• Offer in-office laser rental services to healthcare providers.
• Provide the Sentinel service program for system protection and maintenance.

How Does SRTS Make Money?

• Generate revenue through the sale of radiation therapy devices and related products.
• Offer service programs and maintenance contracts for ongoing customer support.
• Provide disposable items that ensure safety and compliance in treatment environments.
• Engage in partnerships with healthcare facilities to expand product reach.
• Focus on research and development to innovate and enhance product offerings.

What Industry Does SRTS Operate In?

The medical device industry is witnessing robust growth, driven by increasing healthcare expenditures and a rising prevalence of chronic diseases, including skin cancers. The market for radiation therapy devices is expanding, with a growing preference for non-invasive treatment options among patients and healthcare providers. Sensus Healthcare, Inc. is positioned within this evolving landscape, offering specialized solutions that cater to the demand for effective cancer treatments. The competitive landscape includes various established players, but Sensus's focus on superficial radiation therapy differentiates it from traditional surgical methods and other radiation therapies, allowing it to carve out a niche market.

Who Are SRTS's Key Customers?

• Healthcare providers, including hospitals and outpatient clinics.
• Dermatologists and oncologists specializing in skin cancer treatments.
• Patients seeking non-invasive treatment options for skin conditions.
• Medical institutions looking for advanced radiation therapy solutions.
• Distributors of medical devices and supplies.

Company Profile

Sensus Healthcare, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO Joseph C. Sardano. SRTS has traded publicly since 2016.

Return on equity for Sensus Healthcare, Inc. stands at -15.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.6%, the inverse of the P/E and a quick read on earnings relative to price.

SRTS Valuation & Market Position

With a $53.2M market cap, Sensus Healthcare, Inc. sits in the micro-cap segment of the market. Relative to its peer group, SRTS's quantitative score of 29/100 is below the peer average of 74/100.

Quarterly Financial Performance: Sensus Healthcare, Inc.

Revenue for Sensus Healthcare, Inc. came in at $2.3M during Q2 2026, a 32.5% contraction versus the preceding quarter. The company recorded a net loss of $8.7M, with diluted EPS of $-0.53. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, SRTS averaged $-0.23 in diluted EPS.

Sensus Healthcare, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.67 places it in the safe zone, indicating low near-term bankruptcy risk.

Sensus Healthcare, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 120.3% below estimates on average.

Wall Street analysts project Sensus Healthcare, Inc. revenue of about $19.1M for fiscal 2026, with EPS near $-0.79.

SRTS Financials

SRTS Latest News

SRTS Analyst Consensus

SRTS MoonshotScore

Latest Sensus Healthcare, Inc. Analysis

Common Questions About SRTS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources